Antibody Holds Type 1 Diabetes Treatment Promise
Antibody Holds Type 1 Diabetes Treatment Promise . Type 1 diabetes, which usually appears in children and adolescents, affects over 30 million people worldwide. Resulting from an autoimmune reaction that destroys the pancreatic beta cells that produce insulin, the disease leads to pathologically high levels of sugar in the blood (hyperglycemia) and urine, resulting in high rates of morbidity and mortality. The current treatment for Type 1 diabetes is lifetime administration of insulin by injection.
Working at the Hebrew University of Jerusalem, Prof. Ofer Mandelboim identified an important role played by a protein receptor called NKp46 in the development of Type 1 diabetes. Mandelboim is a professor and researcher at the Lautenberg Center for Immunology and Cancer Research at IMRIC — the Institute for Medical Research Israel-Canada, in the Hebrew University’s Faculty of Medicine.
Prof. Mandelboim and his research collaborators found that the NKp46 receptor present on Natural Killer or NK cells (an essential part of the immune system) plays a critical role in the development of the disease in mice. This happens because the NKp46 receptor recognizes pancreatic beta cells, leading to their destruction.
The research also showed that inhibiting the NKp46 receptor almost entirely prevented the development of diabetes. If replicated in humans, this effect could significantly delay, and potentially prevent, the need for chronic insulin use by Type 1 diabetes patients, and help minimize diabetes-related complications.
This groundbreaking research is the basis for BioLineRx’s BL-9020, a monoclonal antibody that targets the Natural Killer receptor NKp46.
Yissum, the technology transfer company of the Hebrew University, together with partners, signed an exclusive license agreement with BioLineRx to develop and commercialize BL-9020 for the treatment of Type 1 diabetes. BioLineRx is a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates.
Development and Commercialization
In January 2014, BioLineRx entered into a collaboration agreement with JHL Biotech for the further development and commercialization of BL-9020 in China and additional Southeast Asia countries. The Type 1 diabetes market was estimated at over $3.5 billion in 2012.
Studies in mouse models suggest that BL-9020 can inhibit beta cell death in the pancreas, thus preventing full maturation of Type 1 diabetes. In humans it could potentially treat Type 1 diabetes in early stage patients, during what is known as the “honeymoon period,” when the pancreatic beta cells have not been completely destroyed and continue to secrete insulin.
While this research is encouraging, mice have been cured of type 1 diabetes many times without the same results occurring in humans. Mice are a good starting place, but much work remains to prove this antibody can help prevent type 1 diabetes in humans. We hope it is true, but we watch with restraint.
Until we have a cure for type 1 diabetes, it is our opinion that mastering this disease in the healthiest way possible through lifestyle innovations as a priority over drug therapies is vital. It is important for optimal blood sugar control today, but it can help put your body in a position of strength for tomorrow – for that day when the cure for type 1 diabetes may be found.
Our recipe e-books, workshops and home study course will teach you how to transform your lifestyle in a practical, livable way for long term sustainability and better living. Our support services can make the difference between success and failure during your transformation. And our advanced resources will take you deeper into practical application and underlying research. Let us help you shorten the learning curve to successful lifestyle transformation by setting you on the path toward optimal blood sugar control and better living.
Hebrew University of Jerusalem. “Antibody holds promise for treatment of Type 1 diabetes.” ScienceDaily. ScienceDaily, 7 June 2015. www.sciencedaily.com/releases/2015/06/150607214213.htm